Dr. Adelson on Bortezomib plus Fulvestrant for HR+ Breast Cancer
Kerin Adelson, MD, Assistant Professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai, explains the results of a phase II clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.
Kerin Adelson, MD, Assistant Professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai, explains the results of a phase II clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.
Fulvestrant was initially approved at a 250mg dose, but it was later determined that the dose was inadequate, says Adelson. In this study, a 500mg dose was used, based on evidence that this dose was more effective from previous trials.
Bortezomib has only been used in liquid tumors, and prior to this study showed no single agent efficacy for solid tumors. Together, bortezomib plus fulvestrant delayed disease progression in hormone receptor-positive metastatic breast cancer.
